Referanslar

1. Demoly p, Adkinson NF, Brockow K, et al. ınternational Con sensus on drug allergy. Allergy. 2014;69:420-37. [Crossref]  [PubMed]
2. Simons FER, Organization WA. World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Annals of Allergy, Asthma & ımmunology. 2010;104:405- 12. [Crossref]  [PubMed]
3. González-pérez A, Aponte z, vidaurre CF, Rodríguez LAg. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. journal of Allergy and Clinical ımmunology. 2010;125: 1098-104. e1091. [Crossref]  [PubMed]
4. Sole D, ıvancevich jC, Borges mS, et al. Anaphylaxis in Latin America: a report of the online Latin American survey on anaphylaxis (OLASA). Clinics. 2011;66:943-7. [Crossref]  [PubMed]  [PMC]
5. Wood RA, Camargo jr CA, Lieberman p, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. journal of Allergy and Clinical ımmunology. 2014;133:461-7. [Crossref]  [PubMed]
6. Turner pj, gowland mH, Sharma v, et al. ıncrease in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. journal of Allergy and Clinical ımmunology. 2015;135:956-63. e951. [Crossref]  [PubMed]  [PMC]
7. Adinoff A. Anaphylaxis in the United States: An ınvestigation ınto ıts Epidemiology. pediatrics. 2002;110:437-437. [Crossref]
8. Jerschow E, Lin RY, Scaperotti mm, mcginn Ap. Fatal anaphylaxis in the United States, 1999- 2010: temporal patterns and demographic associations. journal of allergy and clinical immunology. 2014;134:1318-28. e1317. [Crossref]  [PubMed]  [PMC]
9. Clark S, Wei W, Rudders SA, Camargo jr CA. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. journal of allergy and clinical immunology. 2014;134: 1125-30. [Crossref]  [PubMed]
10. Liew WK, Williamson E, Tang mL. Anaphylaxis fatalities and admissions in Australia. journal of Allergy and Clinical ımmunology. 2009;123: 434- 42. [Crossref]  [PubMed]
11. motosue mS, Bellolio mF, van Houten HK, Shah ND, Campbell RL. Risk factors for severe anaphylaxis in the United States. Annals of Allergy, Asthma & ımmunology. 2017;119: 356-61. e352. [Crossref]  [PubMed]
12. Cavkaytar O, Karaatmaca B, Cetinkaya pg, et al. Characteristics of drug-induced anaphylaxis in children and adolescents. Allergy & Asthma proceedings. vol 382017.
13. grabenhenrich LB, Dölle S, moneret-vautrin A, et al. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. journal of allergy and clinical immunology. 2016;137:1128- 37. e1121. [Crossref]  [PubMed]
14. Lee jm, greenes DS. Biphasic anaphylactic reactions in pediatrics. pediatrics. 2000;106: 762- 6. [Crossref]  [PubMed]
15. Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. The journal of Allergy and Clinical ımmunology: ın practice. 2019;7:103- 11. [Crossref]  [PubMed]  [PMC]
16. Gülen T, Hägglund H, Dahlen B, Nilsson g. High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-centre experience. Clinical & Experimental Allergy. 2014;44:121-9. [Crossref]  [PubMed]
17. Oussalah A, mayorga C, Blanca m, et al. genetic variants associated with drugs‐induced immediate hypersensitivity reactions: a pRıSmA‐compliant systematic review. Allergy. 2016;71:443-62. [Crossref]  [PubMed]
18. Galvão vR, phillips E, giavina-Bianchi p, Castells mC. Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. The journal of Allergy and Clinical ımmunology: ın practice. 2017;5:816-8. [Crossref]  [PubMed]  [PMC]
19. Jares Ej, Baena-Cagnani CE, SánchezBorges m, et al. Drug-induced anaphylaxis in Latin American countries. The journal of Allergy and Clinical ımmunology: in practice. 2015;3:780-8.
20. Sánchez‐Borges m, Capriles‐Behrens E, Caballero‐Fonseca F. Hypersensitivity to non‐ steroidal anti‐inflammatory drugs in childhood. pediatric allergy and immunology. 2004; 15:376-80. [Crossref]  [PubMed]
21. Stevenson DD, Sanchez-Borges m, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Annals of Allergy, Asthma & ımmunology. 2001;87:177-80. [Crossref]  [PubMed]
22. Aun mv, Blanca m, garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. The journal of Allergy and Clinical ımmunology: ın practice. 2014;2:414-20. [Crossref]  [PubMed]
23. petrakis D, Xepapadaki p, manousakis E, et al. Characteristics of NSAıD hypersensitivity reactions in a pediatric population and the role of diagnostic procedures. ALLERgY. vol 73: WıLEY 111 RıvER ST, HOBOKEN 07030- 5774, Nj USA; 2018:808-809.
24. Kowalski m, makowska j, Blanca m, et al. Hypersensitivity to nonsteroidal anti‐inflammatory drugs (NSAıDs)-classification, diagnosis and management: review of the EAACı/ ENDA# and gA2LEN/HANNA. Allergy. 2011; 66:818-29. [Crossref]  [PubMed]
25. Giavina-Bianchi p, Aun mv, Kalil j. Drug-induced anaphylaxis: is it an epidemic? Current opinion in allergy and clinical immunology. 2018;18:59-65. [Crossref]  [PubMed]
26. Parameters jTFop. Drug allergy: an updated practice parameter. Ann Allergy Asthma ımmunol. 2010;105:259-73. [Crossref]  [PubMed]
27. Kuruvilla m, Khan DA. Anaphylaxis to drugs. ımmunology and Allergy Clinics. 2015;35:303- 19. [Crossref]  [PubMed]
28. Sachs B, Riegel S, Seebeck j, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in germany. Drug safety. 2006;29:1087-100. [Crossref]  [PubMed]
29. Kim S, Lee j, park K, park H, park j. varied incidence of immediate adverse reactions to low‐osmolar non‐ionic iodide radiocontrast media used in computed tomography. Clinical & Experimental Allergy. 2017;47:106-12. [Crossref]  [PubMed]
30. Greenberger pA, patterson R, Radin RC. Two pretreatment regimens for high-risk patients receiving radiographic contrast media. journal of allergy and clinical immunology. 1984;74:540-543. [Crossref]  [PubMed]
31. Böhm ı, morelli j, Nairz K, Silva Hasembank Keller p, Heverhagen jT. myths and misconceptions concerning contrast media-induced anaphylaxis: a narrative review. postgraduate medicine. 2017;129:259-66. [Crossref]  [PubMed]
32. giavina-Bianchi p, patil SU, Banerji A. ımmediate hypersensitivity reaction to chemotherapeutic agents. The journal of Allergy and Clinical ımmunology: ın practice. 2017;5:593- 9. [Crossref]  [PubMed]
33. Markman m, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. journal of Clinical Oncology. 1999;17:1141-1141. [Crossref]  [PubMed]
34. Picard m, pur L, Caiado j, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. journal of Allergy and Clinical ımmunology. 2016;137:1154-64. e1112. [Crossref]  [PubMed]
35. Weiszhár z, Czúcz j, Révész C, Rosivall L, Szebeni j, Rozsnyay z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. European journal of pharmaceutical sciences. 2012;45:492-8. [Crossref]  [PubMed]
36. Markman m, Kennedy A, Webster K, Kulp B, peterson g, Belinson j. paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. journal of clinical oncology. 2000;18:102-102. [Crossref]  [PubMed]
37. Kwon jS, Elit L, Finn m, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. gynecologic oncology. 2002;84:420-5. [Crossref]  [PubMed]
38. Castells mC, Tennant Nm, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. journal of Allergy and Clinical ımmunology. 2008;122:574-80. [Crossref]  [PubMed]
39. Woo m, Hak L, Storm m, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527-33. [Crossref]  [PubMed]
40. Soyer OU, Aytac S, Tuncer A, Cetin m, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. journal of allergy and clinical immunology. 2009;123:895-9. [Crossref]  [PubMed]
41. Picard m, galvão vR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. The journal of Allergy and Clinical ımmunology: ın practice. 2017;5: 600-9. [Crossref]  [PubMed]
42. Chung CH, mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and ıgE specific for galactose-α-1, 3-galactose. New England journal of medicine. 2008;358:1109-17. [Crossref]  [PubMed]  [PMC]
43. O'meara S, Nanda KS, moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. ınflammatory bowel diseases. 2014;20:1-6. [Crossref]  [PubMed]
44. Maneiro jR, Salgado E, gomez-Reino jj. ımmunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. jAmA internal medicine. 2013;173:1416-28. [Crossref]  [PubMed]
45. Van Vollenhoven RF, Emery p, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. The journal of rheumatology. 2010;37:558-67. [Crossref]  [PubMed]
46. Jung j-W, Kang H-R, Lee S-H, Cho S-H. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology. 2014;86:127-34. [Crossref]  [PubMed]
47. Ellis AK, Day jH. ıncidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Annals of Allergy, Asthma & ımmunology. 2007;98:64-9. [Crossref]  [PubMed]
48. Lee S, Bellolio mF, Hess Ep, Campbell RL. predictors of biphasic reactions in the emergency department for patients with anaphylaxis. The journal of Allergy and Clinical ımmunology: ın practice. 2014;2:281-7. [Crossref]  [PubMed]
49. Aun mv, Kalil j, giavina-Bianchi p. Drug-induced anaphylaxis. ımmunology and Allergy Clinics. 2017;37:629-41. [Crossref]  [PubMed]
50. Malinovsky jm, Decagny S, Wessel F, guilloux L, mertes p. Systematic follow‐up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta anaesthesiologica scandinavica. 2008;52:175-81. [Crossref]  [PubMed]
51. Gastaminza g, martinez-Albelda ı, gonzálezmahave ı, muñoz D. Study of hypersensitivity reactions and anaphylaxis during anesthesia in Spain. j ınvestig Allergol Clin ımmunol. 2008;18:350-6.
52. Berroa F, Lafuente A, javaloyes g, et al. The incidence of perioperative hypersensitivity reactions: a single-center, prospective, cohort study. Anesthesia & Analgesia. 2015;121:117-23. [Crossref]  [PubMed]
53. Laguna j, Archilla j, Dona ı, et al. practical guidelines for perioperative Hypersensitivity Reactions. journal of investigational allergology & clinical immunology. 2018;28:216-32. [Crossref]  [PubMed]
54. Christiansen ı, Krøigaard m, mosbech H, Skov p, poulsen L, garvey L. Clinical and diagnostic features of perioperative hypersensitivity to cefuroxime. Clinical & Experimental Allergy. 2015;45:807-14. [Crossref]  [PubMed]
55. Garvey LH, Ebo Dg, mertes pm, et al. An EAACı position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74:1872-84. [Crossref]  [PubMed]
56. garvey LH. perioperative hypersensitivity reactions: diagnosis, treatment and evaluation. Current Treatment Options in Allergy. 2016; 3:113-28. [Crossref]
57. Dewachter p, mouton-Faivre C, Emala CW, Beloucif S. Case scenario: bronchospasm during anesthetic induction. Anesthesiology: The journal of the American Society of Anesthesiologists. 2011;114:1200-10. [Crossref]  [PubMed]
58. Sadleir p, Clarke R, Bunning D, platt p. Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011. British journal of anaesthesia. 2013;110:981-7. [Crossref]  [PubMed]
59. Tacquard C, Collange O, gomis p, et al. Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th gERAp epidemiologic survey. Acta Anaesthesiologica Scandinavica. 2017;61:290-9. [Crossref]  [PubMed]
60. Cook T, Harper N, Farmer L, et al. Anaesthesia, surgery, and life-threatening allergic reactions: protocol and methods of the 6th National Audit project (NAp6) of the Royal College of Anaesthetists. British journal of anaesthesia. 2018;121:124-33. [Crossref]  [PubMed]
61. De pater g, Florvaag E, johansson S, ırgens Å, petersen m, guttormsen A. Six years without pholcodine; Norwegians are significantly less ıgE‐sensitized and clinically more tolerant to neuromuscular blocking agents. Allergy. 2017;72:813-19. [Crossref]  [PubMed]
62. Baldo B. Sugammadex and hypersensitivity. Anaesthesia and intensive care. 2014;42:525.
63. Gonzalez-Estrada A, pien LC, zell K, Wang XF, Lang Dm. Antibiotics are an important identifiable cause of perioperative anaphylaxis in the United States. The journal of Allergy and Clinical ımmunology: ın practice. 2015;3:101- 5. e101. [Crossref]  [PubMed]
64. Heise garvey L. Old, new and hidden causes of perioperative hypersensitivity. Current pharmaceutical design. 2016;22:6814-24. [Crossref]  [PubMed]
65. Asserhøj L, mosbech H, Krøigaard m, garvey L. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut. BjA: British journal of Anaesthesia. 2016;116:77-82. [Crossref]  [PubMed]
66. Ozcan j, Nicholls K, jones K. ımmunoglobulin E‐mediated Hypersensitivity Reaction to Ketamine. pain practice. 2016;16:E94-E98. [Crossref]  [PubMed]
67. Dong S, mertes p, petitpain N, Hasdenteufel F, malinovsky j. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). minerva anestesiologica. 2012;78:868.
68. Baldo B, pham N. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesthesia and intensive care. 2012;40:216-35. [Crossref]  [PubMed]
69. Calderon A, Diot N, Benatir F, et al. ımmediate allergic cross‐reactivity to levobupivacaine and ropivacaine. Anaesthesia. 2013;68:203- 5. [Crossref]  [PubMed]
70. Laxenaire m, mertes p, des Réactions Anaphylactoïdes gdE. Anaphylaxis during anaesthesia. Results of a two‐year survey in France. British journal of Anaesthesia. 2001;87:549- 58. [Crossref]  [PubMed]
71. Hepner DL, Castells mC. Anaphylaxis during the perioperative period. Anesthesia & Analgesia. 2003;97:1381-95. [Crossref]  [PubMed]
72. Nybo m, madsen jS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic & clinical pharmacology & toxicology. 2008;103:192-6. [Crossref]  [PubMed]
73. Dietrich W, Späth p, zühlsdorf m, et al. Anaphylactic Reactions to Aprotinin Reexposure in Cardiac SurgeryRelation to Antiaprotinin ımmunoglobulin g and E Antibodies. Anesthesiology: The journal of the American Society of Anesthesiologists. 2001;95:64-71. [Crossref]  [PubMed]
74. Beierlein W, Scheule Am, Dietrich W, ziemer g. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. The Annals of thoracic surgery. 2005;79:741-8. [Crossref]  [PubMed]
75. Wenande E, Kroigaard m, mosbech H, garvey LH. polyethylene glycols (pEg) and related structures: overlooked allergens in the perioperative setting. A & A case reports. 2015;4:61-4. [Crossref]  [PubMed]
76. Wenande E, garvey L. ımmediate‐type hypersensitivity to polyethylene glycols: a review. Clinical & Experimental Allergy. 2016;46:907-22. [Crossref]  [PubMed]
77. Low A, mcEwan j, Karanam S, North j, Kong KL. Anaesthesia‐associated hypersensitivity reactions: seven years' data from a British bi‐specialty clinic. Anaesthesia. 2016;71:76-84. [Crossref]  [PubMed]
78. Opstrup mS, malling Hj, Krøigaard m, et al. Standardized testing with chlorhexidine in perioperative allergy-a large single‐centre evaluation. Allergy. 2014;69:1390-6. [Crossref]  [PubMed]
79. Caballero m, Lukawska j, Dugué p. A hidden cause of perioperative anaphylaxis. journal of investigational allergology & clinical immunology. 2010;20:353.
80. Cooper DE, White AA, Werkema AN, Auge BK. Case report: Anaphylaxis following cystoscopy with equipment sterilized with Cidex® OpA (ortho-phthalaldehyde): a review of two cases. journal of endourology. 2008;22:2181-4. [Crossref]
81. Ramin S, Azar Fp, malihe H. methylene blue as the safest blue dye for sentinel node mapping: emphasis on anaphylaxis reaction. Acta Oncologica. 2011;50:729-31. [Crossref]  [PubMed]
82. Keller B, Yawalkar N, pichler C, Braathen LR, Hunger RE. Hypersensitivity reaction against patent blue during sentinel lymph node removal in three melanoma patients. The American journal of surgery. 2007;193:122-4. [Crossref]  [PubMed]
83. Nubret K, Delhoume m, Orsel ı, Laudy jS, Sellami m, Nathan N. Anaphylactic shock to fresh‐frozen plasma inactivated with methylene blue. Transfusion. 2011;51:125-8. [Crossref]  [PubMed]
84. Katz j, Holzman R, Brown R. Natural rubber latex allergy: consideration for anesthesiologists. park Ridge, ıL: American Society of Anesthesiologists. 2005:1-30.
85. Cabañes N, ıgea j, de La Hoz B, Agustín p, Blanco C, Domínguez j. 1 Latex Allergy: position paper. journal of ınvestigational Allergology and Clinical ımmunology. 2012;22:313.
86. Ewan p, Dugue p, mirakian R, Dixon T, Harper j, Nasser S. BSACı guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clinical & Experimental Allergy. 2010;40:15-31. [Crossref]  [PubMed]
87. Brockow K, Romano A, Blanca m, Ring j, pichler W, Demoly p. general considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57:45-51. [Crossref]  [PubMed]
88. Leysen j, De Witte L, Bridts CH, Ebo Dg. Anaphylaxis during general anaesthesia: a 10-year survey 1 at the University Hospital of Antwerp. proceedings of the Belgian Royal Academies of medicine.-Brussels, 2012, currens. 2013;2:88- 100.
89. Broesby-Olsen S, Oropeza AR, Bindslevjensen C, et al. Recognizing mastocytosis in patients with anaphylaxis: value of KıT D816v mutation analysis of peripheral blood. journal of Allergy and Clinical ımmunology. 2015;135:262- 4. [Crossref]  [PubMed]
90. Ebo D, Fisher m, Hagendorens m, Bridts C, Stevens W. Anaphylaxis during anaesthesia: diagnostic approach. Allergy. 2007;62:471-87. [Crossref]  [PubMed]
91. Mertes pm, moneret-vautrin DA, Leynadier F, Laxenaire m-C. Skin Reactions to ıntradermal Neuromuscular Blocking Agent ınjectionsA Randomized multicenter Trial in Healthy volunteers. Anesthesiology: The journal of the American Society of Anesthesiologists. 2007;107:245-52. [Crossref]  [PubMed]